Cargando…

Serum Cholesteryl Ester Transfer Protein (CETP) and Sortilin (SORT) in Patients with Psoriasis with Relation to Systemic Treatment

Psoriasis is a common inflammatory skin disease, which is tightly associated with metabolic disorders. Cholesteryl ester transfer protein (CETP) and sortilin (SORT) are molecules engaged in lipid metabolism of proatherogenic properties. They have been hardly ever studied in psoriasis before. Serum C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nowowiejska, Julia, Baran, Anna, Krahel, Julita A., Kamiński, Tomasz W., Maciaszek, Magdalena, Flisiak, Iwona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032539/ https://www.ncbi.nlm.nih.gov/pubmed/35448527 http://dx.doi.org/10.3390/metabo12040340

Ejemplares similares

Proprotein Convertase Subtilisin/Kexin Type 9, Angiopoietin-Like Protein 8, Sortilin, and Cholesteryl Ester Transfer Protein—Friends of Foes for Psoriatic Patients at the Risk of Developing Cardiometabolic Syndrome?
por: Krahel, Julita Anna, et al.
Publicado: (2020)

Circulating ANGPTL8 as a Potential Protector of Metabolic Complications in Patients with Psoriasis
por: Baran, Anna, et al.
Publicado: (2023)

Higher Serum Selenoprotein P Level as a Novel Inductor of Metabolic Complications in Psoriasis
por: Baran, Anna, et al.
Publicado: (2020)

Methotrexate Decreases the Level of PCSK9—A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data
por: Krahel, Julita Anna, et al.
Publicado: (2020)

Circulating MAdCAM-1 and ITGB7 in Patients with Plaque Psoriasis and Eruptive Lichen Planus—Preliminary Data
por: Baran, Anna, et al.
Publicado: (2021)

Cholesteryl Ester Transfer Protein (CETP) Deficiency and CETP Inhibitors
por: Mabuchi, Hiroshi, et al.
Publicado: (2014)

Elevated circulating Krüppel-like factor 4 level as a novel independent marker of the proatherogenic risk in patients with psoriasis: a preliminary study
por: Baran, Anna, et al.
Publicado: (2020)

Galectin-3 as a Novel Multifaceted and Not Only Cardiovascular Biomarker in Patients with Psoriasis with Regard to Systemic Treatment—Preliminary Data
por: Baran, Anna, et al.
Publicado: (2022)

The cholesteryl ester transfer protein (CETP) raises cholesterol levels in the brain
por: Oestereich, Felix, et al.
Publicado: (2022)

Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease
por: Schmidt, Amand F., et al.
Publicado: (2021)

Behçet’s Disease in a Polish Patient: A Case Report
por: Nowowiejska, Julia, et al.
Publicado: (2021)

The Potential Role of Serum Tau Protein (MAPT), Neuronal Cell Adhesion Molecule (NrCAM) and Neprilysin (NEP) in Neurodegenerative Disorders Development in Psoriasis—Preliminary Results
por: Baran, Anna, et al.
Publicado: (2022)

Decreased levels of vaspin and its potential association with cardiometabolic risk in patients with psoriasis: preliminary results
por: Kiluk, Paulina, et al.
Publicado: (2021)

Cholesteryl Ester Transfer Protein (CETP) expression does not affect glucose homeostasis and insulin secretion: studies in human CETP transgenic mice
por: Raposo, Helena F., et al.
Publicado: (2016)

Assessment of Life Quality, Stress and Physical Activity Among Patients with Psoriasis
por: Nowowiejska, Julia, et al.
Publicado: (2021)

Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr(−/−) mice
por: Bell, Thomas A., et al.
Publicado: (2013)

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects
por: Thomas, Tiffany, et al.
Publicado: (2017)

The Presence of Cholesteryl Ester Transfer Protein (CETP) in Endothelial Cells Generates Vascular Oxidative Stress and Endothelial Dysfunction
por: Wanschel, Amarylis C. B. A., et al.
Publicado: (2021)

Potential Predictive Value of Serum Pentraxin 3 and Paraoxonase 1 for Cardiometabolic Disorders Development in Patients with Psoriasis—Preliminary Data
por: Baran, Anna, et al.
Publicado: (2022)

Aberrations in Lipid Expression and Metabolism in Psoriasis
por: Nowowiejska, Julia, et al.
Publicado: (2021)

Psoriasis and neurodegenerative diseases—a review
por: Nowowiejska, Julia, et al.
Publicado: (2022)

Fatty Acid-Binding Proteins in Psoriasis—A Review
por: Nowowiejska, Julia, et al.
Publicado: (2022)

The Assessment of Risk and Predictors of Sleep Disorders in Patients with Psoriasis—A Questionnaire-Based Cross-Sectional Analysis
por: Nowowiejska, Julia, et al.
Publicado: (2021)

Fatty Acid-Binding Protein 7 (FABP-7), Glutamic Acid and Neurofilament Light Chain (NFL) as Potential Markers of Neurodegenerative Disorders in Psoriatic Patients—A Pilot Study
por: Nowowiejska, Julia, et al.
Publicado: (2022)

Quantitative Prediction of Human Pharmacokinetics and Pharmacodynamics of CKD519, a Potent Inhibitor of Cholesteryl Ester Transfer Protein (CETP)
por: Choi, Suein, et al.
Publicado: (2019)

Mutual Relationship Between Sleep Disorders, Quality of Life and Psychosocial Aspects in Patients With Psoriasis
por: Nowowiejska, Julia, et al.
Publicado: (2021)

Cholesteryl Ester Transfer Protein (CETP) Polymorphisms Affect mRNA Splicing, HDL Levels, and Sex-Dependent Cardiovascular Risk
por: Papp, Audrey C., et al.
Publicado: (2012)

High-Density Lipoprotein (HDL) Particle Subpopulations in Heterozygous Cholesteryl Ester Transfer Protein (CETP) Deficiency: Maintenance of Antioxidative Activity
por: Chantepie, Sandrine, et al.
Publicado: (2012)

Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure
por: Martinelli, Ana Elisa M., et al.
Publicado: (2018)

Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case
por: Johns, Douglas G., et al.
Publicado: (2019)

Liver fatty acid-binding protein might be a predictive marker of clinical response to systemic treatment in psoriasis
por: Baran, Anna, et al.
Publicado: (2019)

The Level of FGF 21 as a New Risk Factor for the Occurrence of Cardiometabolic Disorders amongst the Psoriatic Patients
por: Kiluk, Paulina, et al.
Publicado: (2019)

Amyloidogenic Properties of a D/N Mutated 12 Amino Acid Fragment of the C-Terminal Domain of the Cholesteryl-Ester Transfer Protein (CETP)
por: García-González, Victor, et al.
Publicado: (2011)

Cholesteryl ester transfer protein (CETP) I405V polymorphism and cardiovascular disease in eastern European Caucasians – a cross-sectional study
por: Bustami, Jasmin, et al.
Publicado: (2016)

Elevated cholesteryl ester transfer and phospholipid transfer proteins aggravated psoriasis in imiquimod-induced mouse models
por: Chen, Jun, et al.
Publicado: (2022)

Evaluation of Plasma Concentrations of Galectins-1, 2 and 12 in Psoriasis and Their Clinical Implications
por: Nowowiejska, Julia, et al.
Publicado: (2023)

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
por: Chapman, M. John, et al.
Publicado: (2010)

Assessing the mechanisms of cholesteryl ester transfer protein inhibitors
por: Zhang, Meng, et al.
Publicado: (2017)

A meta-analytic evaluation of cholesteryl ester transfer protein (CETP) C-629A polymorphism in association with coronary heart disease risk and lipid changes
por: Lin, Shouwei, et al.
Publicado: (2016)

Gasdermin D (GSDMD) Is Upregulated in Psoriatic Skin—A New Potential Link in the Pathogenesis of Psoriasis
por: Nowowiejska, Julia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vuie2o80kcbbum2pgnhgp1ufhg